logo
Plus   Neg
Share
Email

Lilly Posts Trial Data On Postmenopausal Women With Back Pain - Quick Facts

Eli Lilly and Co. (LLY) reported data from a Phase III trial comparing the effects of FORTEO and risedronate on back pain in postmenopausal women with osteoporotic vertebral fractures. The study demonstrated no difference between FORTEO and risedronate on the primary endpoint of at least a 30 percent reduction in worst back pain from baseline to six months of therapy, as assessed by a numeric rating scale in each treatment group.

However, there were statistically significant differences in favor of FORTEO in some exploratory measures, including greater increases in bone mineral density and fewer patients with new vertebral fractures. The trial results are published in the August issue of Osteoporosis International.

The overall safety profile of the study was consistent with the known FORTEO safety profile seen in this patient population, as well as the overall incidence of serious adverse events, treatment-emergent adverse events and adverse events resulting in discontinuation were similar between the FORTEO and risedronate treatment groups. There were nine deaths in the study, four in the FORTEO group and five in the risedronate group, but none of the deaths were considered related to treatment, the company said.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Billionaire entrepreneur Elon Musk on Thursday showed off his concept for the Loop, a high-speed underground public transportation system that will carry up to 16 people and travel at 150 miles per hour. At the Boring Company Information Session, Musk and project leader Steve Davis provided details of the underground mass transit tunnels that the Boring Co. plans to build beneath Los Angeles. Raden has become the second smart luggage company to shut down this month after major U.S. airlines banned smart luggage with non-removable batteries earlier this year. In a statement on its website, Raden said that it is no longer in operation and that all existing shipments have been processed for delivery. The company is shuttering after three years of operation. Shares of AstraZeneca were losing around 2 percent in the London trading after the British drug major reported Friday lower profit in its first quarter amid weak margin, despite growth in product sales. Further, the company reiterated its outlook for fiscal 2018. The level of Externalisation Revenue, divestment timing and investment in launches impacted the overall results.
Follow RTT